Standardized incidence ratios and risk factors for cancer in patients with systemic sclerosis: Data from the Spanish Scleroderma Registry (RESCLE).

Autor:	Carbonell C; Department of Internal Medicine, Hospital Universitario de Salamanca, Universidad de Salamanca-IBSAL, Salamanca, Spain., Marcos M; Department of Internal Medicine, Hospital Universitario de Salamanca, Universidad de Salamanca-IBSAL, Salamanca, Spain. Electronic address: mmarcos@usal.es., Guillén-Del-Castillo A; Unit of Autoimmune Diseases, Department of Internal Medicine, Hospital Universitario Vall d'Hebron, Barcelona, Spain., Rubio-Rivas M; Unit of Autoimmune Diseases, Department of Internal Medicine, Hospital Universitario de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain., Argibay A; Unit of Systemic Autoimmune Diseases and Thrombosis, Department of Internal Medicine, Complejo Hospitalario Universitario de Vigo. Vigo, Pontevedra, Spain., Marín-Ballvé A; Unit of Autoimmune Diseases, Department of Internal Medicine, Hospital Clínico Universitario Lozano Blesa, IIS Aragón. Zaragoza, Spain., Rodríguez-Pintó I; Department of Internal Medicine, Hospital Universitario Mútua Terrassa, Terrassa, Barcelona, Spain., Baldà-Masmiquel M; Unit of Systemic Autoimmune Diseases, Department of Internal Medicine, Consorci Hospitalari de Vic. Vic, Barcelona, Spain., Callejas-Moraga E; Department of Internal Medicine, Parc Taulí, Hospital Universitario, Sabadell, Barcelona, Spain., Colunga D; Department of Internal Medicine, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain., Sáez-Comet L; Department of Internal Medicine, Hospital Universitario Miguel Servet, Zaragoza, Spain., González-Echávarri C; Autoimmune Diseases Research Unit, Department of Internal Medicine, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain., Ortego-Centeno N; Inst Invest Biosanitaria Ibs Granada. Department of Internal Medicine, Unit of Systemic Autoimmune Diseases. Department of Medicine, Facultad de Medicina. Hospital Universitario San Cecilio. Granada. Spain., Marí-Alfonso B; Department of Internal Medicine, Parc Taulí, Hospital Universitario, Sabadell, Barcelona, Spain., Vargas-Hitos JA; Department of Internal Medicine. Hospital Universitario Virgen de las Nieves. Granada, Spain., Todolí-Parra JA; Department of Internal Medicine. Hospital Universitario y Politécnico La Fe. Valencia, Spain., Trapiella L; Department of Internal Medicine, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain., Herranz-Marín MT; Department of Internal Medicine. Hospital General Universitario 'J.M. Morales Meseguer', Murcia, Spain., Freire M; Unit of Autoimmune Diseases, Department of Internal Medicine. Hospital Clínico Universitario de Santiago. Santiago de Compostela, A Coruña, Spain., Castro-Salomó A; Department of Internal Medicine. Hospital Universitario Sant Joan. Reus, Tarragona, Spain., Perales-Fraile I; Department of Internal Medicine. Hospital Universitario Rey Juan Carlos. Móstoles, Madrid, Spain., Madroñero-Vuelta AB; Department of Internal Medicine. Hospital General San Jorge. Huesca, Spain., Sánchez-García ME; Department of Internal Medicine. Hospital Universitario Virgen de Valme. Sevilla, Spain., Ruiz-Muñoz M; Department of Internal Medicine. Hospital Universitario Fundación Alcorcón. Alcorcón, Madrid, Spain., González-García A; Department of Internal Medicine. Hospital Universitario Ramón y Cajal. Madrid, Spain., Sánchez-Redondo J; Department of Internal Medicine. Hospital Universitario de Móstoles. Móstoles, Madrid, Spain., de-la-Red-Bellvis G; Unit of Systemic Autoimmune Diseases, Department of Internal Medicine. Fundació Hospital de l'Esperit Sant. Santa Coloma de Gramenet, Barcelona, Spain., Fernández-Luque A; Department of Internal Medicine. Hospital de Mollet. Mollet del Vallès, Barcelona, Spain., Muela-Molinero A; Department of Internal Medicine. Complejo Asistencial Universitario de León. León, Spain., Lledó GM; Department of Autoimmune Diseases. Hospital Clinic. Barcelona, Spain., Tolosa-Vilella C; Department of Internal Medicine, Parc Taulí, Hospital Universitario, Sabadell, Barcelona, Spain., Fonollosa-Pla V; Unit of Autoimmune Diseases, Department of Internal Medicine, Hospital Universitario Vall d'Hebron, Barcelona, Spain., Chamorro AJ; Department of Internal Medicine, Hospital Universitario de Salamanca, Universidad de Salamanca-IBSAL, Salamanca, Spain., Simeón-Aznar CP; Unit of Autoimmune Diseases, Department of Internal Medicine, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
Jazyk:	angličtina
Zdroj:	Autoimmunity reviews [Autoimmun Rev] 2022 Oct; Vol. 21 (10), pp. 103167. Date of Electronic Publication: 2022 Aug 02.
DOI:	10.1016/j.autrev.2022.103167
Abstrakt:	Aim: Patients with systemic sclerosis (SSc) are at increased risk of cancer, a growing cause of non-SSc-related death among these patients. We analyzed the increased cancer risk among Spanish patients with SSc using standardized incidence ratios (SIRs) and identified independent cancer risk factors in this population. Material and Methods: Spanish Scleroderma Registry data were analyzed to determine the demographic characteristics of patients with SSc, and logistic regression was used to identify cancer risk factors. SIRs with 95% confidence intervals (CIs) relative to the general Spanish population were calculated. Results: Of 1930 patients with SSc, 206 had cancer, most commonly breast, lung, hematological, and colorectal cancers. Patients with SSc had increased risks of overall cancer (SIR 1.48, 95% CI 1.36-1.60; P < 0.001), and of lung (SIR 2.22, 95% CI 1.77-2.73; P < 0.001), breast (SIR 1.31, 95% CI 1.10-1.54; P = 0.003), and hematological (SIR 2.03, 95% CI 1.52-2.62; P < 0.001) cancers. Cancer was associated with older age at SSc onset (odds ratio [OR] 1.22, 95% CI 1.01-1.03; P < 0.001), the presence of primary biliary cholangitis (OR 2.35, 95% CI 1.18-4.68; P = 0.015) and forced vital capacity <70% (OR 1.8, 95% CI 1.24-2.70; P = 0.002). The presence of anticentromere antibodies lowered the risk of cancer (OR 0.66, 95% CI 0.45-0.97; P = 0.036). Conclusions: Spanish patients with SSc had an increased cancer risk compared with the general population. Some characteristics, including specific autoantibodies, may be related to this increased risk. Competing Interests: Declaration of Competing Interest The authors declare that they have no conflict of interest, including any financial, personal, or other relationship within 3 years of beginning this research with a person or organization that could have inappropriately influenced, or be perceived to influence, this work. (Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect